Intra-cellular Therapies, Inc. (ITCI) Tops Q2 EPS by 8c

Intra-cellular Therapies, Inc. (NASDAQ: ITCI) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $319.2 thousand versus the consensus estimate of $410 thousand.

For earnings history and earnings-related data on Intra-cellular Therapies, Inc. (ITCI) click here.

You May Also Be Interested In

• AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
• BofA Securities previews Netflix (NFLX) earnings
• Barclays on Rivian (RIVN) into earnings: 'Autonomy remains show me'